The use of FXR agonists, such as GW4064 and 6-ECDCA, can significantly promote liver cells’ uptake of bile salts to reduce cholestasis and then restore bile flow and reduce serum cholestatic indicators (Ye et al., 2009; Zollner and Trauner, 2009). Here, NR1H4 is linked to cholestasis.